| First Author | Andrews LP | Year | 2021 |
| Journal | Immunity | Volume | 54 |
| Issue | 10 | Pages | 2209-2217.e6 |
| PubMed ID | 34551314 | Mgi Jnum | J:312516 |
| Mgi Id | MGI:6790281 | Doi | 10.1016/j.immuni.2021.08.029 |
| Citation | Andrews LP, et al. (2021) A Cre-driven allele-conditioning line to interrogate CD4(+) conventional T cells. Immunity 54(10):2209-2217.e6 |
| abstractText | CD4(+) T cells share common developmental pathways with CD8(+) T cells, and upon maturation, CD4(+) T conventional T (Tconv) cells lack phenotypic markers that distinguish these cells from FoxP3(+) T regulatory cells. We developed a tamoxifen-inducible ThPOK(CreERT2.hCD2) line with Frt sites inserted on either side of the CreERT2-hCD2 cassette, and a Foxp3(Ametrine-FlpO) strain, expressing Ametrine and FlpO in Foxp3(+) cells. Breeding these mice resulted in a CD4conv(iCreERT2-hCD2) line that allows for the specific manipulation of a gene in CD4(+) Tconv cells. As FlpO removes the CreERT2-hCD2 cassette, CD4(+) Treg cells are spared from Cre activity, which we refer to as allele conditioning. Comparison with an E8I(iCreERT2.GFP) mouse that enables inducible targeting of CD8(+) T cells, and deletion of two inhibitory receptors, PD-1 and LAG-3, in a melanoma model, support the fidelity of these lines. These engineered mouse strains present a resource for the temporal manipulation of genes in CD4(+) T cells and CD4(+) Tconv cells. |
